TLDR
- GSK is purchasing Nuvalent for $10.6 billion in an all-cash transaction, offering $124 per share — representing a 40% premium over Monday’s closing price
- Shares of GSK declined by up to 3% during early London market hours after the acquisition announcement
- Nuvalent’s portfolio includes two leading candidates targeting non-small-cell lung cancer, both awaiting regulatory decisions from the FDA in the coming months
- The transaction is projected to boost revenue and operating profit starting in 2027, with positive core EPS impact beginning in 2029
- GSK maintains its 2026 full-year outlook of 7–9% core EPS growth remains unchanged despite the acquisition
In a major strategic move, GSK has announced its intention to purchase Nuvalent through an all-cash transaction valued at $10.6 billion. The pharmaceutical giant is offering $124 for each share — representing a substantial 40% premium above Nuvalent’s Monday closing price.
Following Tuesday’s announcement, GSK stock experienced a decline of up to 3% during early trading hours in London. Despite this setback, the shares have gained approximately 23% over the trailing twelve-month period.
Nuvalent’s shares had been experiencing downward pressure throughout the current year, declining roughly 12% prior to the acquisition announcement, which had brought its market capitalization to approximately $7 billion.
This represents the most significant acquisition since Luke Miels assumed the CEO position from Emma Walmsley at the beginning of 2026. It marks his second major transaction this year, following the $2.2 billion purchase of Rapt Therapeutics announced in January.
GSK plans to finance the acquisition primarily through a combination of new borrowing, existing debt facilities, and available cash reserves. The company has stated that the deal structure will not negatively impact its current credit rating.
Dual Late-Stage Cancer Therapy Assets
The two principal drug candidates in Nuvalent’s pipeline are designed for non-small-cell lung cancer patients who carry specific genetic alterations — mutations predominantly found in individuals who have never smoked. Both therapies are currently in advanced-stage clinical development and are expected to receive FDA regulatory decisions later in 2026.
According to GSK, both therapeutic candidates possess blockbuster sales potential upon regulatory approval. Additionally, the acquisition provides GSK with a technology platform to enhance its experimental antibody-drug conjugate Ris-Rez, which is presently undergoing late-stage clinical evaluation.
Nuvalent specializes in developing precision-targeted oncology treatments. The company’s development pipeline aligns seamlessly with Miels’ strategic vision — establishing a more robust late-stage cancer drug portfolio.
GSK’s oncology division experienced impressive 43% growth in 2025, reaching just under £2 billion in sales, although this represents merely 6% of the company’s total £32.7 billion revenue base.
By comparison, competitor AstraZeneca derives 44% of its overall revenue from oncology products. While GSK has considerable ground to cover in closing this disparity, the Nuvalent acquisition represents a significant stride toward that objective.
Addressing the Oncology Deficit — Lessons from AstraZeneca
GSK divested its oncology assets in 2014 through an exchange agreement with Novartis. Meanwhile, AstraZeneca pursued the opposite strategy, committing heavily to cancer therapeutics under the leadership of CEO Pascal Soriot — a decision that yielded substantial returns.
Miels previously held an executive position at AstraZeneca. His appointment was broadly interpreted as an indication that GSK sought to implement elements of that successful strategy.
The Nuvalent transaction will not alter GSK’s 2026 full-year projections, which continue to target 7–9% core EPS expansion. The company anticipates low single-digit earnings per share dilution spanning from 2026 through 2028.
Revenue additions are anticipated to commence in 2027, while positive core EPS contribution is expected to materialize in 2029. After accounting for cash acquired, GSK’s net investment is calculated at $9.4 billion.
The deal is scheduled to finalize in the third quarter of 2026, subject to customary regulatory clearances.
Miels has publicly stated his ambition to achieve revenue exceeding £40 billion by 2031 and to fortify the development pipeline in advance of the 2028 patent expiration for HIV treatment dolutegravir.
